BIIB (Biogen Idec) Market Value to Book Value Ratio

Official company branding of Biogen Inc (BIIB)

Biogen Inc. operates high-tech centers in Europe and the US, ensuring the flawless quality of its biologics. The company is currently implementing cutting-edge Alzheimer's research to neutralize pressure from generics. The high scalability potential of the biotech sector allows expensive R&D to be converted into monopoly profits. Analyzing the current market-to-book ratio on GURU.Markets, we see that the parameter has stabilized at 1.98.

BIIB - biogen.com Market-to-Book Ratio over the range 07/04/2022 - 10/27/2026

Financial and market metric breakdowns for Biogen Inc (BIIB)

- price and consensus price forecast:
Stock Price Biogen Inc.|BIIB - Price Target Chart
- market capitalization data:
Market Value Biogen Corp|BIIB - Business Value
- book capitalization data:
Book Value per Share Biogen|BIIB - Total Stockholders' Equity|Market Cap to Net Assets Ratio biogen.com|BIIB - Company Total Assets
- debt and liquidity data:
Debt to Equity Biogen Inc.|BIIB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Biogen Corp|BIIB - Company Cumulative Debt|Debts to Book Capitalization Biogen Corp
Initial company analysis:Biogen Inc.
Original product of Biogen Corp

This indicator reflects the gap between the business's market valuation and its net assets, allowing for an immediate market reaction to corporate events. By analyzing the ratio of market capitalization to the book value of Biogen Inc. (BIIB), an investor can see how R&D risks in Alzheimer's disease treatment impact the speculative premium over the company's real capital value.

Competitor analysis

Neurocrine Biosciences (NBIX) - Market Capitalization to Book Value Ratio|RGC (regencellbioscience.com) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Axsome Therapeutics, Inc. (AXSM)|Capitalization to Book Value Ratio ACADIA Pharma|Xenon Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Viking Therapeutics Corp VKTX|Market Cap to Net Assets Ratio SUPN (Supernus Pharmaceuticals)|catalystpharma.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Denali Therapeutics Inc. (DNLI)|HRMY: Market Value to Book Value|Market Value to Book Value Ratio BHVN|Amylyx Corp (AMLX) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Trevi Therapeutics|Market Value to Book Value Ratio praxismedicines.com|AVXL (Anavex Life Sciences Corp.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value CBLL (CeriBell Inc)|PRTA: Market Value to Book Value Ratio|Market-to-Book Ratio Alector Inc. ALEC|Market Capitalization to Book Value Ratio ANNX|OMER - Market Value to Equity Ratio|Market Capitalization to Book Value Ratio NGNE|ACIU (AC Immune S.A.) - Market-to-Book Ratio|Market Value to Book Value Ratio Voyager Pharma (VYGR)|Capitalization to Book Value Ratio Neumora Corp (NMRA)|Scilex Holding Company (SCLX) - Market Cap to Net Assets Ratio|Market Value to Book Value tevogen.com (TVGN)|Market Capitalization to Book Value Ratio ACOG|cogrx.com - Market Capitalization to Book Value|Inhibikase (IKT) - Market Value to Book Value Ratio|SAVA - Capitalization to Book Value Ratio|ASRT (assertiotx.com) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Coya Therapeutics|VTGN: Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ovid Rx|Market Capitalization to Book Value Ratio Acumen Pharma (ABOS)|Market Value to Book Value Ratio CervoMed Corporation (CRVO)|Market Capitalization to Book Value Ratio ATHE|Market Capitalization to Book Value Clene Inc CLNN|Market Capitalization to Book Value Ratio PEPG (PepGen Corp)|JUNS - Market Capitalization to Book Value|Relmada (RLMD) - Market Capitalization to Book Value Ratio|ANVS (Annovis Bio Corporation) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Grace Therapeutics Inc (GRCE)|Capitalization to Book Value Ratio fireflyneuro.com|Klotho Neurosciences Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio neurosense-tx.com NRSN|Market Cap to Net Assets Ratio RVPH (Reviva Pharmaceuticals Holdings)|MetaVia Inc. - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NeurAxis, Inc. (NRXS)|HSDT: Market Value to Book Value|Market Value to Book Value Ratio PASG|Neuphoria Therapeutics (NEUP) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Minerva Neurosciences Corp|Market Value to Book Value Ratio Athira Pharma Corp|ADXN (Addex Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value ALZN (alzamend.com)|CYCN: Market Value to Book Value Ratio|Market-to-Book Ratio Protagenic Therapeutics Inc. PTIX|Market Capitalization to Book Value Ratio KTTA|CRGT - Market Value to Equity Ratio|Market Capitalization to Book Value Ratio ATXI|BCLI (brainstorm-cell.com) - Market-to-Book Ratio|Market Value to Book Value Ratio Cara Therapeutics (CARA)|Capitalization to Book Value Ratio Chromocell Therapeutics Corp (CHRO)|Eliem Therapeutics (ELYM) - Market Cap to Net Assets Ratio|Market Value to Book Value intracellulartherapies.com (ITCI)|Market Capitalization to Book Value Ratio LBPH|marinuspharma.com - Market Capitalization to Book Value|NKGen Biotech (NKGN) - Market Value to Book Value Ratio|NRBO - Capitalization to Book Value Ratio|SAGE (Sage Therapeutics, Inc) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Synaptogenix, Inc|TRVN: Market Cap to Net Assets Ratio|Market Capitalization to Book Value Vigil Neuro|Market Capitalization to Book Value Ratio Anew Medical, Inc. (WENA)|Market Value to Book Value Ratio Cerevel Therapeutics Inc (CERE)